Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 7/20 | 0.42 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834830 | 0.92 | NAMPT (0.51) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19851922 | 0.91 | NAMPT (0.48) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19834844 | 0.85 | NAMPT (0.69) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19842196 | 0.82 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19851883 | 0.82 | NAMPT (0.69) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19834853 | 0.81 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19842221 | 0.81 | NAMPT (0.48) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19834823 | 0.80 | NAMPT (0.46) | NAMPTCYP3A4CYP2C9BCHEACHE | |
| SCHEMBL19842220 | 0.80 | NAMPT (0.49) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL19834878 | 0.79 | NAMPT (0.52) | NAMPTCYP3A4CYP2C9BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| WO-2018024907-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | RNASE1, PKD1, GPR6 | NAMPT 1437/4885CYP3A4 2988/4885CYP2C9 4330/4885 |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | RNASE1, PKD1, GPR6 | NAMPT 1265/4885CYP3A4 2393/4885CYP2C9 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.